1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY TYPE OF FLU
5.1. Introduction
5.2. Type A
5.3. Type B
6. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY OFFERING
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. Others
6.3. Therapeutics
7. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY AGE GROUP
7.1. Introduction
7.2. 0-14 Years
7.3. 15-64 Years
7.4. >=65 Years
8. IRAN FLU DIAGNOSTIC AND TREATMENT MARKET BY END-USER
8.1. Introduction
8.2. Hospital Laboratory
8.3. Outpatient Clinic
8.4. Reference Laboratory
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. AryoGen Pharmed.
10.2. CinnaGen.
10.3. Pasteur Institute of Iran.
10.4. Mahban Darou (Mahbaflu).
10.5. Nafas Zist Pharmed.
10.6. Pooyesh Darou.
10.7. ProGnosis Biotech.
10.8. Roche.
10.9. Hana Gene
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES